US Stock MarketDetailed Quotes
THAR Tharimmune
- 2.965
- -0.115-3.73%
Close Jun 18 16:00 ET
- 2.890
- -0.075-2.53%
Post 19:23 ET
2.33MMarket Cap-132P/E (TTM)
3.150High2.920Low41.45KVolume2.950Open3.080Pre Close125.93KTurnover5.37%Turnover RatioLossP/E (Static)786.03KShares163.08852wk High0.33P/B2.29MFloat Cap2.75052wk Low--Dividend TTM771.80KShs Float1590.000Historical High--Div YieldTTM7.47%Amplitude2.750Historical Low3.037Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Tharimmune Stock Forum
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, al...
Sold for now with loss. Not looking good to hold for long time. Pullback phase was on already
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with
TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune, a clinical-stage biotech firm, announced positive Phase 1 trial results for TH104, its lead candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC). The study in healthy subjects showed that the pharmacokinetic (PK) profile of oral transmucosal TH104 was comparable to i...
No comment yet